Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases

Payal Saxena, Guang Chen, Bilel Jideh, Glen Collins, Rupert W. Leong*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry